Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer

This phase III trial compares the addition of induction chemotherapy, with carboplatin, paclitaxel and pembrolizumab, to chemotherapy and radiation, with cisplatin and pembrolizumab followed by pembrolizumab maintenance for the treatment of patients with cervical cancer that has spread to nearby tissue or lymph nodes (locally advanced). Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of cancer cells

Trial Details

NCT ID
NCT07061977
Phase
PHASE3
Sponsor
National Cancer Institute (NCI)
Status
RECRUITING
Cancer Type
Cervical Cancer
Interventions
  • Biospecimen Collection
  • Brachytherapy
  • Carboplatin
  • Chest Radiography
  • Cisplatin
  • Computed Tomography
Locations (sample)
  • Birmingham, Alabama, United States|33.52066,-86.80249
  • Fayetteville, Arkansas, United States|36.06258,-94.15743
  • Little Rock, Arkansas, United States|34.74648,-92.28959
  • Rogers, Arkansas, United States|36.33202,-94.11854
  • Springdale, Arkansas, United States|36.18674,-94.12881

Key Eligibility Criteria

  • Patients must have pathologically confirmed newly diagnosed cervical cancer. Eligible pathologic types: squamous cell carcinoma, adenocarcinoma, ad…
  • Patients must have locally advanced cervical cancer (LACC) with T3 or T4 disease with or without lymph node involvement:
  • IIIA (T3aN0M0)
  • IIIB (T3bN0M0)

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Cervical Cancer Trials on Trialify →